These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 8967274)
1. [Prevention of cerebral vasospasms after experimental subarachnoid hemorrhage by the endothelin receptor antagonist RO 47-0203]. Zimmermann M; Seifert V Zentralbl Neurochir; 1996; 57(3):143-9. PubMed ID: 8967274 [TBL] [Abstract][Full Text] [Related]
2. Prevention of cerebral vasospasm after experimental subarachnoid hemorrhage by RO 47-0203, a newly developed orally active endothelin receptor antagonist. Zimmermann M; Seifert V; Löffler BM; Stolke D; Stenzel W Neurosurgery; 1996 Jan; 38(1):115-20. PubMed ID: 8747959 [TBL] [Abstract][Full Text] [Related]
3. Endothelin in cerebral vasospasm. Clinical and experimental results. Zimmermann M J Neurosurg Sci; 1997 Jun; 41(2):139-51. PubMed ID: 9385564 [TBL] [Abstract][Full Text] [Related]
4. The role of endothelin in experimental cerebral vasospasm. Roux S; Löffler BM; Gray GA; Sprecher U; Clozel M; Clozel JP Neurosurgery; 1995 Jul; 37(1):78-85; discussion 85-6. PubMed ID: 8587695 [TBL] [Abstract][Full Text] [Related]
5. The effect of bosentan, a new potent endothelin receptor antagonist, on the pathogenesis of cerebral vasospasm. Shigeno T; Clozel M; Sakai S; Saito A; Goto K Neurosurgery; 1995 Jul; 37(1):87-90; discussion 90-1. PubMed ID: 8587696 [TBL] [Abstract][Full Text] [Related]
6. Prevention of subarachnoid hemorrhage-induced cerebral vasospasm by oral administration of endothelin receptor antagonists. Zuccarello M; Soattin GB; Lewis AI; Breu V; Hallak H; Rapoport RM J Neurosurg; 1996 Mar; 84(3):503-7. PubMed ID: 8609565 [TBL] [Abstract][Full Text] [Related]
8. The role of endothelin and nitric oxide in modulation of normal and spastic cerebral vascular tone in the dog. Hirose H; Ide K; Sasaki T; Takahashi R; Kobayashi M; Ikemoto F; Yano M; Nishikibe M Eur J Pharmacol; 1995 Apr; 277(1):77-87. PubMed ID: 7635177 [TBL] [Abstract][Full Text] [Related]
9. Systemic administration of the endothelin-A receptor antagonist TBC 11251 attenuates cerebral vasospasm after experimental subarachnoid hemorrhage: dose study and review of endothelin-based therapies in the literature on cerebral vasospasm. Wanebo JE; Arthur AS; Louis HG; West K; Kassell NF; Lee KS; Helm GA Neurosurgery; 1998 Dec; 43(6):1409-17; discussion 1417-8. PubMed ID: 9848855 [TBL] [Abstract][Full Text] [Related]
10. Prevention of vasospasm after subarachnoid hemorrhage in dogs by continuous intravenous infusion of PD156707. Macdonald RL; Johns L; Lin G; Marton LS; Hallak H; Marcoux F; Kowalczuk A Neurol Med Chir (Tokyo); 1998; 38 Suppl():138-45. PubMed ID: 10234996 [TBL] [Abstract][Full Text] [Related]
11. Effect of EGb-761 on vasospasm in experimental subarachnoid hemorrhage. Kurtsoy A; Canbay S; Oktem IS; Akdemir H; Koç RK; Menkü A; Tucer B Res Exp Med (Berl); 2000 Feb; 199(4):207-15. PubMed ID: 10743678 [TBL] [Abstract][Full Text] [Related]
12. Effect of endothelin-1 receptor antagonist BQ-123 on basilar artery diameter after subarachnoid hemorrhage (SAH) in rats. Jośko J; Hendryk S; Jedrzejowska-Szypułka H; Słowiński J; Gwóźdź B; Lange D; Harabin-Słowińska M J Physiol Pharmacol; 2000 Jun; 51(2):241-9. PubMed ID: 10898097 [TBL] [Abstract][Full Text] [Related]
13. Prevention of delayed vasospasm by an endothelin ETA receptor antagonist, BQ-123: change of ETA receptor mRNA expression in a canine subarachnoid hemorrhage model. Itoh S; Sasaki T; Asai A; Kuchino Y J Neurosurg; 1994 Nov; 81(5):759-64. PubMed ID: 7931624 [TBL] [Abstract][Full Text] [Related]
14. Effect of endothelinA-receptor antagonist BQ-123 and phosphoramidon on cerebral vasospasm. Cosentino F; McMahon EG; Carter JS; Katusić ZS J Cardiovasc Pharmacol; 1993; 22 Suppl 8():S332-5. PubMed ID: 7509979 [TBL] [Abstract][Full Text] [Related]
15. Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm. Roux S; Breu V; Giller T; Neidhart W; Ramuz H; Coassolo P; Clozel JP; Clozel M J Pharmacol Exp Ther; 1997 Dec; 283(3):1110-8. PubMed ID: 9399983 [TBL] [Abstract][Full Text] [Related]
16. Prevention of cerebral vasospasm by actinomycin D. Shigeno T; Mima T; Yanagisawa M; Saito A; Goto K; Yamashita K; Takenouchi T; Matsuura N; Yamasaki Y; Yamada K J Neurosurg; 1991 Jun; 74(6):940-3. PubMed ID: 2033454 [TBL] [Abstract][Full Text] [Related]
17. An endothelin ETA receptor antagonist, FR139317, ameliorates cerebral vasospasm in dogs. Nirei H; Hamada K; Shoubo M; Sogabe K; Notsu Y; Ono T Life Sci; 1993; 52(23):1869-74. PubMed ID: 8318117 [TBL] [Abstract][Full Text] [Related]
18. Clazosentan, an endothelin receptor antagonist, prevents early hypoperfusion during the acute phase of massive experimental subarachnoid hemorrhage: a laser Doppler flowmetry study in rats. Schubert GA; Schilling L; Thomé C J Neurosurg; 2008 Dec; 109(6):1134-40. PubMed ID: 19035733 [TBL] [Abstract][Full Text] [Related]
19. Reversal of subarachnoid hemorrhage-induced vasoconstriction with an endothelin receptor antagonist. Foley PL; Caner HH; Kassell NF; Lee KS Neurosurgery; 1994 Jan; 34(1):108-12; discussion 112-3. PubMed ID: 8121547 [TBL] [Abstract][Full Text] [Related]
20. A novel endothelin ETA receptor antagonist, BQ-485, and its preventive effect on experimental cerebral vasospasm in dogs. Itoh S; Sasaki T; Ide K; Ishikawa K; Nishikibe M; Yano M Biochem Biophys Res Commun; 1993 Sep; 195(2):969-75. PubMed ID: 8373429 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]